Endometrial cancer

Last reviewed: 6 Nov 2022
Last updated: 31 Mar 2021



History and exam

Key diagnostic factors

  • postmenopausal vaginal bleeding (PVB)
More key diagnostic factors

Other diagnostic factors

  • uterine mass, fixed uterus, or adnexal mass indicating extrauterine disease
  • abnormal menstruation or vaginal bleeding in a premenopausal woman
  • pain (abdominal or pelvic) and weight loss
  • symptoms of metastatic disease
  • signs of metastatic disease
Other diagnostic factors

Risk factors

  • overweight and obesity
  • inactivity
  • smoking
  • age >50 years
  • endometrial hyperplasia
  • unopposed endogenous estrogen
  • unopposed exogenous estrogen
  • tamoxifen use (postmenopausal women)
  • insulin resistance
  • family history of endometrial cancer
  • family history of breast cancer or ovarian cancer
  • family history of hereditary nonpolyposis colorectal cancer (Lynch syndrome)
  • family history of PTEN syndromes
  • nulliparity and infertility
  • polycystic ovary syndrome
  • radiation therapy
  • white ethnicity
More risk factors

Diagnostic investigations

1st investigations to order

  • pelvic (transvaginal) ultrasound
  • office-based endometrial biopsy (with or without office-based hysteroscopy) and histopathology
  • hysteroscopy, dilation and curettage (D&C), and histopathology
  • Pap smear
  • CBC
More 1st investigations to order

Investigations to consider

  • serum CA-125 level
  • saline infusion sonohysterogram
  • BUN and creatinine (renal function testing)
  • LFTs
  • chest x-ray
  • CT scan of chest, abdomen, and pelvis
  • MRI of uterus, pelvis, and abdomen
  • PET/CT scan
More investigations to consider

Treatment algorithm


stage IA endometrioid carcinoma not considering fertility preservation

stage IA endometrioid carcinoma considering fertility preservation

stage IB or II endometrioid carcinoma

stages III to IV endometrioid carcinoma; all nonendometrioid carcinomas (high risk)


recurrent or incurable disease



Alexander B. Olawaiye, MD, MRCOG, FACOG, FACS
Alexander B. Olawaiye

Associate Professor

Division of Gynecologic Oncology

Department of Obstetrics, Gynecology, and Reproductive Sciences

Magee-Womens Hospital of UPMC

University of Pittsburgh School of Medicine




ABO declares that he has no competing interests.

Richard T. Penson, MD, MRCP
Richard T. Penson

Clinical Director

Medical Gynecologic Oncology

Division of Hematology Oncology

Massachusetts General Hospital




RTP declares that he is on the scientific advisory boards of: Genentech, Inc., AstraZeneca, Endocyte, Inc., Eisai Inc., Vascular Biogenics Ltd, Baxalta Oncology, AbbVie, Clovis Oncology, Roche, and Merck. RTP receives research funding from: Genentech, Inc., ImClone Systems, Inc., Endocyte, Inc., AstraZeneca., Eisai Inc., Amgen Inc., and Vascular Biogenics Ltd. RTP was an expert witness for Aventis Pharma S.A. Vs. Apotex Inc in 2009. RTP has received royalties from: BMJ, Blackwell Publishing Medicine at a glance, and UpToDate Advance Medical: Second Medical Opinion.

Larissa J. Lee, MD
Larissa J. Lee

Assistant Professor

Department of Radiation Oncology

Brigham and Women’s Hospital/Dana-Farber Cancer Institute




LJL receives institutional funding for investigator-initiated immunotherapy trial from AstraZeneca; Grant funding from the Koch Institute at MIT and DFCI; sponsored travel from AstraZeneca for immunotherapy symposium; and has an international patent filing for quantitative tumor oxygen measurements in cervical cancer.


Dr Alexander B. Olawaiye, Dr Richard T. Penson, and Dr Larissa J. Lee would like to gratefully acknowledge Dr Neil S. Horowitz and Dr Anthony H. Russell, previous contributors to this topic.


NSH and AHR declare that they have no competing interests.

Peer reviewers

Susan A. Davidson, MD

Associate Professor/Chief

Gynecologic Oncology

S/M Obstetrics & Gynecology (UCD)

University of Colorado Health Sciences Center




SAD declares that she has no competing interests.

Svetlana Mironov, MD

Attending Radiologist

Assistant Professor of Radiology

Memorial Sloan-Kettering Cancer Center

New York



SM declares that she has no competing interests.

  • Endometrial cancer images
  • Differentials

    • Endometrial hyperplasia
    • Endometrial polyp
    • Endometriosis
    More Differentials
  • Guidelines

    • ACR appropriateness criteria: pretreatment evaluation and follow-up of endometrial cancer
    • NCCN clinical practice guidelines in oncology: uterine neoplasms
    More Guidelines
  • Patient leaflets


    More Patient leaflets
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer